Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022
11 Julio 2022 - 8:44AM
Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage
biopharmaceutical company pioneering the development of
exosome-based therapeutics as a new class of medicines, today
announced that management will be attending the William Blair
Biotech Focus Conference 2022 in New York City. Codiak’s Chief
Executive Officer, Douglas E. Williams, Ph.D., will participate in
a panel discussion entitled “Developing Therapies for the Next
Immuno-Oncology Targets,” on Tuesday, July 12 from 4:10 - 5:20 pm
ET and the Company will also be hosting one-on-one meetings at the
conference.
About Codiak BioSciences Codiak is
a clinical-stage biopharmaceutical company pioneering the
development of exosome-based therapeutics, a new class of medicines
with the potential to transform the treatment of a wide spectrum of
diseases with high unmet medical need. By leveraging the biology of
exosomes as natural intercellular transfer mechanisms, Codiak has
developed its proprietary engEx® Platform to expand upon the innate
properties of exosomes to design, engineer and manufacture novel
exosome therapeutic candidates. Codiak has utilized its engEx
Platform to generate a deep pipeline of engineered exosomes aimed
at treating a broad range of disease areas, spanning oncology,
neuro-oncology, infectious disease and rare disease. For more
information, please visit www.codiakbio.com.
Forward-Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among other things, statements concerning the clinical
development and therapeutic potential of exoSTING and exoIL-12. Any
forward-looking statements in this press release are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. For a discussion of
these risks and uncertainties, and other important factors, any of
which could cause our actual results to differ from those contained
in the forward-looking statements, see the section entitled “Risk
Factors” in Codiak’s Annual Report on Form 10-K for the
year ended December 31, 2021, and in subsequent filings with
the Securities and Exchange Commission, as well as discussions of
potential risks, uncertainties and other important factors in
Codiak’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is current as of
the date of this report, and Codiak undertakes no duty to update
this information unless required by law.
Investor Contact:Christopher
TaylorVP, Investor Relations and Corporate Communications T:
617-949-4220E: investor@codiakbio.com
Media Contact:Cory TrombleeScient
PRmedia@codiakbio.com
Codiak BioSciences (NASDAQ:CDAK)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Codiak BioSciences (NASDAQ:CDAK)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Codiak BioSciences Inc (NASDAQ): 0 recent articles
Más de Artículos de Noticias